MA27483A1 - Derives d'azole-pyrimidines fondues - Google Patents
Derives d'azole-pyrimidines fonduesInfo
- Publication number
- MA27483A1 MA27483A1 MA28247A MA28247A MA27483A1 MA 27483 A1 MA27483 A1 MA 27483A1 MA 28247 A MA28247 A MA 28247A MA 28247 A MA28247 A MA 28247A MA 27483 A1 MA27483 A1 MA 27483A1
- Authority
- MA
- Morocco
- Prior art keywords
- azole
- pathologies
- disease
- pyrimidine derivatives
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne de nouveaux dérivés d'azole-pyrimidines fondues, des procédés permettant de les préparer et des préparations pharmaceutiques les contenant. Les dérivés d'azole-pyrimidines fondues de la présente invention présentent une capacité renforcée d'inhibition de la phosphotidylinositol-3-kinase (P13K), notamment d'inhibition de la P13K-(gamma) et peuvent s'utiliser pour assurer la prophylaxie et le traitement de pathologies associées à la P13K et en particulier à l'activité de la P13K-(gamma). Les dérivés d'azole de la présente invention s'utilisent plus particulièrement dans le traitement et la prophylaxie des pathologies suivantes : troubles inflammatoires et immunorégulateurs. tels que l'asthme, la dermatite atopique, la rhinite, les maladies allergiques, la maladie pulmonaire obstructive chronique (COPD), le choc septique, les maladies des articulations, les pathologies auto-immunes telles que la polyarthrite rhumatoïde, et la maladie de Graves, le cancer, les troubles de contractilité du myocarde, l'insuffisance cardiaque, le thromboembolisme, l'ischémie et l'athérosclérose. Les composés de la présente invention s'utilisent également pour traiter l'hypertension pulmonaire, l'insuffisance rénale, l'hypertrophie cardiaque, de même que des troubles neurodégénératifs tels que la maladie de Parkinson, la maladie d'Alzheimer, le diabète et l'ischémie focale, ces pathologies se rapportant également à l'activité de la P13K, chez l'homme ou l'animal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02021861 | 2002-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27483A1 true MA27483A1 (fr) | 2005-08-01 |
Family
ID=32039115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28247A MA27483A1 (fr) | 2002-09-30 | 2005-04-29 | Derives d'azole-pyrimidines fondues |
Country Status (33)
Country | Link |
---|---|
US (2) | US7511041B2 (fr) |
EP (2) | EP1549652B1 (fr) |
JP (1) | JP4790266B2 (fr) |
KR (1) | KR101059652B1 (fr) |
CN (1) | CN100384846C (fr) |
AR (2) | AR041426A1 (fr) |
AT (2) | ATE411996T1 (fr) |
AU (1) | AU2003293310B2 (fr) |
BR (1) | BRPI0314830B8 (fr) |
CA (1) | CA2499134C (fr) |
CY (2) | CY1109790T1 (fr) |
DE (1) | DE60324296D1 (fr) |
DK (2) | DK1549652T3 (fr) |
EC (2) | ECSP055768A (fr) |
ES (2) | ES2367141T3 (fr) |
HK (1) | HK1084393A1 (fr) |
HR (2) | HRP20050375B1 (fr) |
IL (1) | IL166855A (fr) |
MA (1) | MA27483A1 (fr) |
MX (1) | MXPA05001808A (fr) |
MY (1) | MY140756A (fr) |
NO (1) | NO331457B1 (fr) |
NZ (1) | NZ539062A (fr) |
PE (1) | PE20050089A1 (fr) |
PL (1) | PL226562B1 (fr) |
PT (2) | PT1549652E (fr) |
RU (1) | RU2326881C9 (fr) |
SI (2) | SI1549652T1 (fr) |
TW (1) | TWI327570B (fr) |
UA (1) | UA82205C2 (fr) |
UY (1) | UY28001A1 (fr) |
WO (1) | WO2004029055A1 (fr) |
ZA (1) | ZA200503306B (fr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
CA2537124C (fr) | 2003-08-29 | 2012-08-07 | Mitsui Chemicals, Inc. | Insecticide s'utilisant en agriculture ou en horticulture et procede d'utilisation correspondant |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
CA2579279C (fr) | 2004-10-07 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Derives de thiazole tricyclique en tant que pi3-kinases |
WO2006040645A1 (fr) * | 2004-10-11 | 2006-04-20 | Ranbaxy Laboratories Limited | Derives de benzamide n-(3,5-dichloropyridine-4-yle)-2,4,5-alcoxy et 2,3,4 alcoxy en tant qu'inhibiteurs de pde-iv (phosphodiesterase de type iv) pour traiter des maladies inflammatoires telles que l'asthme |
EP3770278A1 (fr) | 2005-04-14 | 2021-01-27 | The Trustees of Boston University | Diagnostic des troubles pulmonaires à l'aide d'une prédiction de classe |
UA97348C2 (en) * | 2005-07-29 | 2012-02-10 | 4Сц Аг | HETEROCYCLIC NF-kB INHIBITORS |
CA2645310A1 (fr) | 2006-03-09 | 2007-09-13 | The Trustees Of Boston University | Methodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de genes de cellules epitheliales nasales |
US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
US7517995B2 (en) * | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
ATE532788T1 (de) * | 2006-04-26 | 2011-11-15 | Hoffmann La Roche | Pharmazeutische verbindungen |
WO2008064244A2 (fr) * | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Modulation des phosphoinositides pour le traitement de maladies neurodégénératives |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
EP1953163A1 (fr) * | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dérivés de Pteridinone comme inhibiteurs des Kinases PI3 |
WO2008148023A2 (fr) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions et procédés pour traiter des troubles neurologiques |
WO2009039140A1 (fr) * | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kinase p13 |
EP2193211A4 (fr) * | 2007-09-19 | 2010-12-08 | Univ Boston | Identification de nouvelles voies pour le développement de médicaments destinés à traiter une maladie des poumons |
JP5620275B2 (ja) * | 2008-01-14 | 2014-11-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
WO2009111547A1 (fr) * | 2008-03-04 | 2009-09-11 | Wyeth | Composés de 7h-pyrrolo[2,3-h]quinazoline, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3-kinase, et leur synthèse |
WO2009128520A1 (fr) * | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | Composé hétérocyclique présentant une activité inhibitrice sur p13k |
EP2303890A4 (fr) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | Inhibiteurs de phosphatidylinositol 3 kinase |
EP2168582A1 (fr) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées |
EP2168583A1 (fr) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome |
ES2614130T3 (es) * | 2008-09-30 | 2017-05-29 | Pfizer Inc. | Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones |
BRPI0915273B1 (pt) * | 2008-11-11 | 2021-08-03 | Je Il Pharmaceutical Co., Ltd | Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
ES2674719T3 (es) | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
CA2750935A1 (fr) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryles et applications associees |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
EP2411391A1 (fr) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation |
CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
SI2899191T1 (sl) * | 2009-04-30 | 2017-11-30 | Glaxo Group Limited | Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
NZ626650A (en) * | 2009-09-09 | 2015-12-24 | Celgene Avilomics Res Inc | Pi3 kinase inhibitors and uses thereof |
MX2012012064A (es) * | 2010-04-16 | 2012-12-17 | Bayer Ip Gmbh | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. |
WO2012021611A1 (fr) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations de ceux-ci |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
CN103370320B (zh) * | 2010-11-11 | 2016-04-27 | 拜耳知识产权有限责任公司 | 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 |
ES2646012T3 (es) | 2010-11-11 | 2017-12-11 | Bayer Intellectual Property Gmbh | 2,3-Dihidroimidazo[1,2-c]quinazolinas sustituidas con alcoxi |
UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
EP2508525A1 (fr) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés |
AR090253A1 (es) | 2012-03-05 | 2014-10-29 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona |
EP2968988A4 (fr) | 2013-03-14 | 2016-11-16 | Allegro Diagnostics Corp | Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd) |
US20160143910A1 (en) | 2013-03-15 | 2016-05-26 | Constellation Pharmaceuticals, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
PE20151780A1 (es) | 2013-04-08 | 2015-12-20 | Bayer Pharma AG | Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas |
WO2014177060A1 (fr) | 2013-05-01 | 2014-11-06 | F.Hoffmann-La Roche Ag | Composés bihétéroaryle et leurs utilisations |
WO2015027431A1 (fr) * | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | Antagonistes 2,2-difluorodioxolo du récepteur a2a |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
MX2016008259A (es) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. |
SG11201609877XA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
EP3770274A1 (fr) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée |
EP3018127A1 (fr) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthèse de copanlisib et son sel de dichlorhydrate |
EP3018131A1 (fr) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthèse de copanlisib et son sel de dichlorhydrate |
SG11201707240SA (en) | 2015-03-09 | 2017-10-30 | Bayer Pharma AG | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
WO2017153220A1 (fr) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
EP3219329A1 (fr) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinaisons de copanlisib |
US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
JP2019532922A (ja) | 2016-09-23 | 2019-11-14 | バイエル ファーマ アクチエンゲゼルシャフト | Pi3k−阻害剤の組み合わせ |
WO2018112176A1 (fr) | 2016-12-14 | 2018-06-21 | Tarveda Therapeutics, Inc. | Conjugués ciblant hsp90 et formulations de ces derniers |
EP3585437B1 (fr) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinaisons de copanlisib avec un anticorps anti-pd-1 |
CA3068324A1 (fr) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combinaison d'un inhibiteur de pi3k et d'un antagoniste du recepteur des androgenes |
HUE063178T2 (hu) | 2017-09-08 | 2023-12-28 | Bayer Pharma AG | Kopanlizib formulációi |
EP3498266A1 (fr) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations de copanlisib |
JP7394768B2 (ja) * | 2017-09-20 | 2023-12-08 | エイビーエム セラピューティックス コーポレイション | キナーゼ阻害剤としての環状イミノピリミジン誘導体 |
US11351156B2 (en) | 2017-10-13 | 2022-06-07 | Inserm | Combination treatment of pancreatic cancer |
WO2019101871A1 (fr) | 2017-11-23 | 2019-05-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Nouveau marqueur permettant de prédire la sensibilité à des inhibiteurs de pi3k |
WO2019105734A1 (fr) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinaisons de copanlisib |
WO2019105835A1 (fr) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinaisons de copanlisib et d'anetumab ravtansine |
WO2019197269A1 (fr) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinaisons de copanlisib et de dérivés de triazolone ainsi que leur utilisation dans le traitement du cancer |
WO2020020385A1 (fr) * | 2018-07-27 | 2020-01-30 | 上海翰森生物医药科技有限公司 | Inhibiteur de dérivé tricyclique, son procédé de préparation et application |
CN109053554B (zh) * | 2018-08-01 | 2020-07-28 | 江苏八巨药业有限公司 | 一种使用催化剂合成3-乙酰吡啶的方法 |
EP3843743A1 (fr) | 2018-08-28 | 2021-07-07 | Bayer AS | Combinaison d'inhibiteurs de pi3k et de conjugués de thorium ciblés |
WO2020078788A1 (fr) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline |
CA3118493A1 (fr) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion de til utilisant des inhibiteurs de la voie akt |
EP3903828A4 (fr) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase |
WO2020164997A1 (fr) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combinaison d'inhibiteurs de la pi3k |
CN114621236B (zh) * | 2022-04-25 | 2024-06-18 | 河南湾流生物科技有限公司 | 一种喹啉类饲料添加剂的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644354A (en) * | 1968-09-16 | 1972-02-22 | Sandoz Ag | 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines |
US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
CN1033644C (zh) * | 1993-01-02 | 1996-12-25 | 瑞安大药厂股份有限公司 | 3-取代甲基-2,3-二氢咪唑并[1,2-c]喹唑啉衍生物,其制备与用途 |
WO1996004923A1 (fr) | 1994-08-12 | 1996-02-22 | Pro-Neuron, Inc. | Procedes permettant de traiter la sepsie ou des maladies inflammatoires avec des nucleosides a base d'oxypurine |
WO1997027177A2 (fr) * | 1996-01-29 | 1997-07-31 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Derives de dihydropyridine-, pyridine-, benzopyrane- mono- et triazoloquinazoline, leur preparation, et utilsation comme antagonistes des recepteurs de l'adenosine |
US5932584A (en) * | 1997-05-06 | 1999-08-03 | National Science Council | Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof |
ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
DE60144322D1 (de) * | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
-
2003
- 2003-09-18 MX MXPA05001808A patent/MXPA05001808A/es active IP Right Grant
- 2003-09-18 ES ES08075839T patent/ES2367141T3/es not_active Expired - Lifetime
- 2003-09-18 AT AT03788908T patent/ATE411996T1/de active
- 2003-09-18 PT PT03788908T patent/PT1549652E/pt unknown
- 2003-09-18 US US10/527,376 patent/US7511041B2/en not_active Expired - Lifetime
- 2003-09-18 JP JP2004538935A patent/JP4790266B2/ja not_active Expired - Lifetime
- 2003-09-18 DK DK03788908T patent/DK1549652T3/da active
- 2003-09-18 CN CNB038233673A patent/CN100384846C/zh not_active Expired - Lifetime
- 2003-09-18 PT PT08075839T patent/PT2042504E/pt unknown
- 2003-09-18 EP EP03788908A patent/EP1549652B1/fr not_active Expired - Lifetime
- 2003-09-18 WO PCT/EP2003/010377 patent/WO2004029055A1/fr active Application Filing
- 2003-09-18 KR KR1020057005434A patent/KR101059652B1/ko active IP Right Grant
- 2003-09-18 SI SI200331490T patent/SI1549652T1/sl unknown
- 2003-09-18 RU RU2005113165/04A patent/RU2326881C9/ru active
- 2003-09-18 ES ES03788908T patent/ES2312843T3/es not_active Expired - Lifetime
- 2003-09-18 AT AT08075839T patent/ATE511510T1/de active
- 2003-09-18 CA CA2499134A patent/CA2499134C/fr not_active Expired - Lifetime
- 2003-09-18 DE DE60324296T patent/DE60324296D1/de not_active Expired - Lifetime
- 2003-09-18 NZ NZ539062A patent/NZ539062A/en not_active IP Right Cessation
- 2003-09-18 DK DK08075839.4T patent/DK2042504T3/da active
- 2003-09-18 SI SI200332036T patent/SI2042504T1/sl unknown
- 2003-09-18 AU AU2003293310A patent/AU2003293310B2/en not_active Expired
- 2003-09-18 PL PL375935A patent/PL226562B1/pl unknown
- 2003-09-18 UA UAA200504176A patent/UA82205C2/uk unknown
- 2003-09-18 BR BRPI0314830A patent/BRPI0314830B8/pt active IP Right Grant
- 2003-09-18 EP EP08075839A patent/EP2042504B1/fr not_active Expired - Lifetime
- 2003-09-29 PE PE2003000986A patent/PE20050089A1/es active IP Right Grant
- 2003-09-29 TW TW092126767A patent/TWI327570B/zh not_active IP Right Cessation
- 2003-09-29 UY UY28001A patent/UY28001A1/es active IP Right Grant
- 2003-09-29 AR ARP030103542A patent/AR041426A1/es active IP Right Grant
- 2003-09-29 MY MYPI20033701A patent/MY140756A/en unknown
-
2005
- 2005-02-14 IL IL166855A patent/IL166855A/en active IP Right Grant
- 2005-04-25 ZA ZA200503306A patent/ZA200503306B/en unknown
- 2005-04-27 NO NO20052076A patent/NO331457B1/no not_active IP Right Cessation
- 2005-04-27 HR HRP20050375AA patent/HRP20050375B1/hr not_active IP Right Cessation
- 2005-04-28 EC EC2005005768A patent/ECSP055768A/es unknown
- 2005-04-29 MA MA28247A patent/MA27483A1/fr unknown
-
2006
- 2006-04-19 HK HK06104675.8A patent/HK1084393A1/xx not_active IP Right Cessation
-
2009
- 2009-01-09 CY CY20091100017T patent/CY1109790T1/el unknown
- 2009-03-30 US US12/414,257 patent/US8129386B2/en not_active Expired - Lifetime
- 2009-07-01 AR ARP090102458A patent/AR072458A2/es not_active Application Discontinuation
-
2011
- 2011-02-07 EC EC2011005768A patent/ECSP11005768A/es unknown
- 2011-08-10 CY CY20111100771T patent/CY1112174T1/el unknown
-
2013
- 2013-12-04 HR HRP20131159A patent/HRP20131159B1/hr not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27483A1 (fr) | Derives d'azole-pyrimidines fondues | |
Neueder et al. | The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients | |
MXPA04004019A (es) | Derivados de pirimido?4,5-b?indol. | |
MA30318B1 (fr) | Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4 | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
ATE187447T1 (de) | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel | |
TNSN04111A1 (fr) | Derives de quinazoline pour le traitement d'une croissance cellulaire anormale | |
Nandakishore et al. | Selective cyclooxygenase inhibitors: current status | |
MA27491A1 (fr) | Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip | |
MA24694A1 (fr) | Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant. | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
ES2104424T3 (es) | Compuestos de isoxazolina como agentes antiinflamatorios. | |
MA33772B1 (fr) | Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques | |
MA31862B1 (fr) | Anticorps anti-mésothéline et leurs utilisations | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
WO2001012171A3 (fr) | Composition et procede neurotherapeutiques a base de clavulanate | |
Cougnoux et al. | Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin | |
MA31397B1 (fr) | Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés | |
MA35567B1 (fr) | Nouvelle formulation de méloxicam | |
MA32798B1 (fr) | Acides naphtylacétiques | |
TW200502221A (en) | Novel lactams and uses thereof | |
EA200500172A1 (ru) | Азабициклопроизводные в качестве антагонистов мускариновых рецепторов | |
JP2010248224A (ja) | 治療又は予防薬 | |
MA27690A1 (fr) | Composition pharmaceutique androgene et procede pour le traitement de la depression. | |
MA44018B1 (fr) | Dérivés de tétrahydroisoquinoline |